Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis

NCT06479863 is registered in ClinicalTrials.gov with Austin Neuromuscular Center as lead sponsor.

NCT NCT06479863
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06479863 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis
Lead sponsor
Austin Neuromuscular Center
Phase
Phase 1
Overall status
Recruiting
Start date
August 8, 2024
Completion date
August 30, 2027
Enrollment
10 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic inflammatory myopathies, sporadic inclusion body myositis (sibm)